Yea, Mylan's effort at Copaxone seems about as half a$$ed as TEVA's work on Lovenox. Natco's version appears to be only approved in the Ukraine and India. It's kind of sad that $MYL thinks this kind of quality will get through the FDA even if they try to polish it up a little. Do you have any references for work done examining their(Natco's) product? I mean if it is good enough for the Ukraine, why not the FDA? Lol.
$MYL PR related to their agreement with Natco for generic Copaxone(2008) - http://bit.ly/hSCxPp
News 
Market Data 
Discover 
AI
